Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Jul;36(4):229–236. doi: 10.1007/BF01740904

Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy

Maribeth Laude 1, Katherine L Russo 1, Margalit B Mokyr 1, Sheldon Dray 1,✉
PMCID: PMC11038904  PMID: 8439986

Abstract

We show here that in contrast to BALB/c mice bearing a late-stage, large MOPC-315 plasmacytoma, BALB/c mice bearing a late-stage, large RPC-5 plasmacytoma were not cured by cyclophosphamide therapy (15, 50, 100 or 200 mg/kg). However, most BALB/c mice bearing a late-stage RPC-5 tumor were cured by cyclophosphamide therapy (100 mg/kg) in conjunction with adoptive immunotherapy using tumor-infiltrated spleen cells (TISpC) that had been cultured with inactivated RPC-5 tumor cells plus polyethylene glycol 6000, even though this protocol was not effective for the therapy of mice bearing a barely palpable, early-stage RPC-5 tumor. Only a few of the mice that were cured of a late-stage RPC-5 tumor following adoptive chemoimmunotherapy (ACIT) were resistant to a subsequent challenge with RPC-5 tumor cells. However, the challenged mice that had developed progressively growing tumors could then be cured by cyclophosphamide alone when the tumor became large, even though this treatment was not curative for mice bearing a tumor of similar size but not previously treated by ACIT. Thus, the cure by ACIT of BALB/c mice bearing a lethal, late-stage RPC-5 tumor with extensive metastases provides a novel experimental tumor model for investigating the mechanisms by which a chemotherapeutic drug and adoptive cellular immunotherapy can cooperate in causing the complete regression of a large tumor load.

Key words: Adoptive chemoimmunotherapy, Late-stage tumors, Cytotoxic T cells, Drug-resistant tumors, Antitumor immunity

Footnotes

Supported by research grant CA-30088 from the National Cancer Institute and IM-435 from the American Cancer Society. M. B. M. was supported by Career Development Award CA-01350 from the National Cancer Institute

This work is a partial fulfillment of the requirements for the Ph.D. degree

References

  • 1.Barth RJ, Jr, Bock SN, Mule JJ, Rosenberg SA. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol. 1990;144:1531–1531. [PubMed] [Google Scholar]
  • 2.Ben-Efraim S, Bocian RC, Mokyr MB, Dray S. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol Immunother. 1983;15:101–101. doi: 10.1007/BF00199699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cheever MA, Greenberg PD, Fefer A. Potential for specific cancer therapy with immune T lymphocytes. J Biol Response Mod. 1984;3:113–113. [PubMed] [Google Scholar]
  • 4.Crowley N, Vervaert CE, Seigler HF. Human xenograft-nude mouse model of adoptive immunotherapy with human melanomaspecific cytotoxic T-cells. Cancer Res. 1992;52:394–394. [PubMed] [Google Scholar]
  • 5.Dray S, Mokyr MB. Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy. Med Oncol Tumor Pharmacother. 1989;6:77–77. doi: 10.1007/BF02985227. [DOI] [PubMed] [Google Scholar]
  • 6.Giorgi JV, Warner NL. Tumor immunity to murine plasmacell tumors: VIII. Immunosuppression of the generation of cytotoxic T-cells by murine plasma-cell tumor lines. Int J Cancer. 1983;32:629–629. doi: 10.1002/ijc.2910320518. [DOI] [PubMed] [Google Scholar]
  • 7.Hengst JCD, Mokyr MB, Dray S. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res. 1980;40:2135–2135. [PubMed] [Google Scholar]
  • 8.Hilgard P, Pohl J, Stekar J, Voegeli R. Oxazaphosphorines as biological response modifiers-experimental and clinical perspectives. Cancer Treat Rev. 1985;12:155–155. doi: 10.1016/0305-7372(85)90036-2. [DOI] [PubMed] [Google Scholar]
  • 9.Ioannides CG, Freedman RS, Platsoucas CD, Rashed S, Kim YP. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol. 1991;146:1700–1700. [PubMed] [Google Scholar]
  • 10.Katzmann JA. Myeloma-induced immunosuppression: a multistep mechanism. J Immunol. 1978;121:1405–1405. [PubMed] [Google Scholar]
  • 11.Laude M, Siessmann KL, Wise JA, Dray S. Cultured CD8 T cells with potent tumor-specific cytotoxic activity and curative in adoptive chemoimmunotherapy. In: Lotze MT, Finn OJ, editors. Cellular immunity and the immunotherapy of cancer. New York: Wiley-Liss; 1990. pp. 243–243. [Google Scholar]
  • 12.Laude M, Siessmann KL, Mokyr MB, Dray S. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas. Cancer Res. 1991;51:4516–4516. [PubMed] [Google Scholar]
  • 13.Mokyr MB, Dray S. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Cancer Res. 1983;43:3112–3112. [PubMed] [Google Scholar]
  • 14.Mokyr MB, Braun DP, Usher D, Reiter H, Dray S. The development of in vitro and in vivo anti-tumor cytotoxicity in noncytotoxic, MOPC-315 tumor-bearer, spleen cells “educated” in vitro with MOPC-315 tumor cells. Cancer Immunol Immunother. 1978;4:143–143. [Google Scholar]
  • 15.Mokyr MB, Hengst JCD, Dray S. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous MOPC-315 tumors. Cancer Res. 1982;42:974–974. [PubMed] [Google Scholar]
  • 16.Mokyr MB, Barker E, Weiskirch LM, Takesue BY, Pyle JM. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res. 1989;49:4597–4597. [PubMed] [Google Scholar]
  • 17.Morikawa K, Hosokawa M, Hamada J, Sugawara M, Kobayashi H. Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma. Cancer Res. 1985;45:1502–1502. [PubMed] [Google Scholar]
  • 18.Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984;225:1487–1487. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  • 19.Nagarkatti M, Toney DM, Nagarkatti PS. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res. 1989;49:6587–6587. [PubMed] [Google Scholar]
  • 20.North RJ, Awwad M. Elimination of cycling CD4+ suppressor T cells with anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology. 1990;71:90–90. [PMC free article] [PubMed] [Google Scholar]
  • 21.North RJ, Digiacomo A, Dye ES. Suppression of antitumor immunity. In: Den Otter W, Ruitenberg EJ, editors. Tumor immunology — mechanisms, diagnosis, therapy. Amsterdam: Elsevier; 1987. pp. 126–126. [Google Scholar]
  • 22.Przepiorka D, Mokyr MB, Dray S. Effect of polyethylene glycol 6000 on the generation of antitumor cytotoxicity in the MOPC-315 tumor bearer spleen cells cultured in the presence or absence of inactivated stimulator tumor cells. Cancer Res. 1980;40:4565–4565. [PubMed] [Google Scholar]
  • 23.Radov LA, Haskill JS, Korn JH. Host immune potentiation of drug responses to a murine mammary adenocarcinoma. Int J Cancer. 1976;17:773–773. doi: 10.1002/ijc.2910170613. [DOI] [PubMed] [Google Scholar]
  • 24.Radov LA, Korn JH, Haskill JS. Host immune potentiation of drug responses to a murine mammary adenocarcinoma: II. Effect of melphalan therapy on the host immune system. Int J Cancer. 1976;18:630–630. doi: 10.1002/ijc.2910180512. [DOI] [PubMed] [Google Scholar]
  • 25.Rosenberg SA. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. JNCI. 1985;75:595–595. [PubMed] [Google Scholar]
  • 26.Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318–1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 27.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med. 1987;316:889–889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 28.Schoof DD, Selleck CM, Massaro AF, Jung S-E, Eberlein TJ. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Cancer Res. 1990;50:1138–1138. [PubMed] [Google Scholar]
  • 29.Shanahan TC, Ceglowski WS, Havas F. Cellular changes in antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment. Cancer Res. 1985;45:6463–6463. [PubMed] [Google Scholar]
  • 30.Shu S, Chou T, Rosenberg SA. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol. 1986;136:3891–3891. [PubMed] [Google Scholar]
  • 31.Topalian SL, Rosenberg SA. Adoptive cellular therapy: basic principles. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: Lippincott; 1991. pp. 178–178. [Google Scholar]
  • 32.Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD. Activation and growth of murine tumor-specific T-cells which have in vivo activity with Bryostatin 1. Cancer Res. 1992;52:548–548. [PubMed] [Google Scholar]
  • 33.Vidovic D, Marusic M, Culo F. Interference of anti-tumor and immunosuppressive effects of cyclophosphamide in tumor-bearing rats. Analysis of factors determining resistance or susceptibility to a subsequent tumor challenge. Cancer Immunol Immunother. 1982;14:36–36. doi: 10.1007/BF00199430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Weiskirch LM, Barker E, Mokyr MB. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother. 1990;31:129–129. doi: 10.1007/BF01744726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Weiskirch LM, Mokyr MB. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Int J Cancer. 1992;51:84–84. doi: 10.1002/ijc.2910510117. [DOI] [PubMed] [Google Scholar]
  • 36.Wise JA, Mokyr MB, Dray S. Enhancement of the effectiveness of Lyt2+ T-cells for adoptive chemoimmunotherapy by shortterm exposure of tumor-bearer spleen cells to polyethylene glycol and/or melphalan. Cancer Res. 1989;49:3616–3616. [PubMed] [Google Scholar]
  • 37.Yang JC, Rosenberg SA. Adoptive cellular therapy. Preclinical studies. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: Lippincott; 1991. pp. 197–197. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES